Recap of Access! 2018 — Successes From the Past Year (Part 1) | Association for Accessible Medicines
Access! 2018 - Keynote Address from The Honorable Eric Hargan, U.S. Department of Health and Human Services

Recap of Access! 2018 — Successes From the Past Year (Part 1)

More than 600 leaders in the field came together last week to celebrate the achievements of the generic and biosimilars industry and to ready themselves for the political and business challenges ahead.

Following an introduction by Emmy-winning journalist John Donvan, Association for Accessible Medicines (AAM) board chair, Apotex President and CEO Jeff Watson, offered his perspective on successes from the past year. Among the association’s many achievements, Jeff highlighted the defeat of the FDA’s problematic draft drug labeling rule, the institution of enhanced FDA approval processes and the FDA’s determination to curtail the abuse of safety programs by some brand companies.

Jeff’s chief message: Get involved in your association. Draw upon AAM’s resources as you navigate the challenges ahead.

AAM equips members with up-to-the-minute statistics and messages so they can personalize and add local nuance to the industry's story. The annual Generic Drug Access and Savings in the U.S. Report and the recently published 2017 Annual Report present these assets clearly.

Download the 2017 Annual Report 

Watch a Recap of Access! 2018

GRx+Biosims 2018

Building on the momentum of Access! 2018, we invite you to mark your calendars for a new combined fall event. GRx+Biosims 2018 is the single best opportunity to hear directly from government officials, learn best practices and connect with peers in the generic and biosimilars industry. This event is coming to Hilton Baltimore, September 5-7. Registration opens soon! Planning on going? Share the news by sharing this tweet

Learn More



Rachel Schwartz

By Rachel Schwartz, AAM Director of Communications

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.